HC Wainwright Reiterates Buy Rating on UNCY
HC Wainwright reaffirms its buy rating on UNCY, setting a $15 price target, a 226.80% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on UNCY, setting a $15 target on June 30, 2026.
- HC Wainwright's $15 price target implies 226.80% upside from Unicycive Therapeutics, Inc.'s ($UNCY) current $4.59 share price.
- Shares of UNCY traded near $4.59 on Tuesday with recent insider buying activity noted in May.
- Other analysts like B. Riley Securities and Benchmark also maintain buy ratings with higher price targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright reiterated its buy rating on UNCY, setting a price target of $15 on June 30, 2026. Analyst Swayampakula Ramakanth maintained the positive outlook, suggesting confidence in the company's future prospects.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in UNCY
VIVO Capital, LLC held its position steady with 1,789,916 shares valued at about $11.78 million. Millennium Management LLC increased its stake by 384,505 shares, ending with 1,399,348 shares worth approximately $9.21 million, marking a significant 37.9% increase. Octagon Capital Advisors LP and Nantahala Capital Management, LLC both maintained their positions, holding 1,000,000 and 939,202 shares, respectively. Vanguard Capital Management LLC opened a new position with 811,430 shares valued at around $5.34 million.
Unicycive Therapeutics, Inc. Stock Down 12.8%
Shares of UNCY traded near $4.59 on Tuesday. The company has seen recent interest from both insiders and institutional investors, reflecting a dynamic market environment.
$UNCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Unicycive Therapeutics, Inc.
On May 14, 2026, several key insiders at UNCY made significant purchases. Pramod Gupta, EVP of Pharmaceuticals and BD, along with EVP of Corporate Strategy Douglas Jermasek, each acquired 169,500 shares. CEO Shalabh Gupta made the largest purchase, acquiring 762,200 shares. Other notable transactions included CFO John Townsend and Sara Kenkare-Mitra, who purchased 169,500 and 126,300 shares, respectively.
Analysts Set New Price Targets
On June 30, 2026, HC Wainwright & Co. maintained its buy rating on UNCY with a $15 price target. B. Riley Securities also maintained a buy rating, but with a higher target of $22. Benchmark and Guggenheim analysts echoed these sentiments, with Benchmark setting an $18 target and Guggenheim a $37 target. The consensus among analysts remains positive, with a strong buy recommendation and an average target price reflecting optimism about UNCY's growth potential.
Bottom Line
HC Wainwright's reaffirmation of a buy rating and a $15 target for UNCY is a notable endorsement. Investors track such analyst updates closely, as they can influence market sentiment. While this reflects past analysis, it's important for investors to consider current market conditions and company developments.
Get Unicycive Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UNCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.